IP Library Granted Patent US 10,927,136
Granted Patent B2
US 10,927,136 · App. 16/315,210 · Granted Feb 23, 2021

Phosphorus prodrugs of pyrazolo-substituted pyrimidine sGC stimulators

Inventors: James Edward Sheppeck (Newtown, PA); Paul Allan Renhowe (Sudbury, MA); Ara Mermerian (Waltham, MA); Timothy Claude Barden (Salem, MA); Glen Robert Rennie (Somerville, MA); Rajesh R. Iyengar (West Newton, MA); Takashi Nakai (Newton, MA)
Assignee: Cyclerion Therapeutics, Inc.
C07F9/65583A61P3/00A61P9/10A61P9/12A61P25/28C07F9/65586
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,927,136
App. No.
16/315,210
Granted
Feb 23, 2021
Kind
B2
Abstract

The present patent application discloses the compounds according to Formula (I) shown below, or pharmaceutically acceptable salts thereof wherein J B , n, R 1 , R 2 , R 3 , R 4 , R 5 , m and X as defined herein.

Claims (50)

1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof,

wherein:

each J B is independently halogen;

R 1 is hydrogen, C 1-4 alkyl, C 1-4 fluoroalkyl, or —C(O)NH 2 ;

R 2 is hydrogen, C 1-4 alkyl, or C 1-4 fluoroalkyl; or

R 1 and R 2 , together with the carbon atom to which they are attached, form an unsubstituted C 3-7 cycloaliphatic ring or an unsubstituted 3- to 7-membered heterocyclic ring, wherein the heterocyclic ring contains 1 or 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur;

R 3 is hydrogen, halogen, cyano, or —NH 2 ;

each R 4 is independently hydrogen; or

two R 4 , together with the carbon atom to which they are attached, form a carbonyl;

R 5 is hydrogen or methyl;

X is:

M + is a pharmaceutically acceptable monovalent cation;

D 2+ is a pharmaceutically acceptable divalent cation;

m is 0 or 1; and

n is 0, 1, 2, 3, or 4.

2. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

(i) R 1 is C 1-4 fluoroalkyl; and

R 2 is C 1-4 fluoroalkyl; or

(ii) R is C 1-2 fluoroalkyl; and

R 2 is C 1-2 fluoroalkyl; or

(iii) R 1 is trifluoromethyl; and

R 2 is trifluoromethyl.

3. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is hydrogen, fluoro, or chloro.

4. The compound according to claim 3 , or a pharmaceutically acceptable salt thereof, wherein R 3 is fluoro.

5. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein X is:

6. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

X is:

and

M + is Na + , K + , Cs + , or the monovalent cation of an organic amine.

7. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

X is:

and

D 2+ is Mg 2+ , Ca 2+ , Zn 2+ , or the divalent cation of an organic amine.

8. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 0.

9. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 1.

10. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, or 2.

11. The compound according to claim 10 , or a pharmaceutically acceptable salt thereof, wherein:

(i) each J B is independently fluoro; or

(ii) each J B is independently chloro; or

(iii) each J B is independently chloro or fluoro.

12. The compound according to claim 1 , wherein the compound is of Formula V:

or a pharmaceutically acceptable salt thereof.

13. The compound according to claim 1 , wherein the compound is of Formula VI:

or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

15. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising one or more excipients and a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2019
From: SHEPPECK, JAMES EDWARD; RENHOWE, PAUL ALLAN; MERMERIAN, ARA; BARDEN, TIMOTHY CLAUDE; RENNIE, GLEN ROBERT; IYENGAR, RAJESH R.; NAKAI, TAKASHI
To: IRONWOOD PHARMACEUTICALS, INC.
Reel/Frame 049399/0625 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 10, 2019
From: IRONWOOD PHARMACEUTICALS, INC.
To: CYCLERION THERAPEUTICS, INC.
Reel/Frame 048853/0001 →